These severe adverse events led to withdrawal or termination of several other ongoing and approved Phase I trials designed to discover the breadth and potency of the anti-tumor effects of 4-1BB agonist immunotherapy (NCT00803374, NCT00309023, NCT00461110, NCT00351325). This evidence concerns the gene TNFRSF9 and neoplasm.